A d o p T r a c e l l
Speeding CAR Evolution Under the Radar
In the Press
AdopTracell Granted Technology Validation Start-up Funding (TVSF Phase II)
February 1, 2022
The Ohio Department of Development has awarded AdopTracell with Technology Validation Start-up Funds (TVSF Phase II) for the company to fully develop its patent protected CAR-Treg immune-therapy for Type 1 Diabetes. These grants (Phase I, proof-of-concept; Phase II, validation) are awarded to young companies that have licensed innovative technologies from research institutions.
AdopTracell Wins iCorps Award
March 15, 2021
Team AdopTracell wins first grant for CAR Treg commercialization path.
The FDA Investigational New Drug filing process officially begins.
Reversal of Autoimmunity with Engineered Adoptive Cell Transfer
May 14, 2020
Our technology becomes public. The news of the discovery of immunosuppresive, antigen-specific CAR Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders is now patented!
February 12, 2019
University of Toledo (formerly Medical College of Ohio) researchers have generated a mouse that mimics the human development and progression of type 1 diabetes, a breakthrough that will open the door to new therapies.